Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

NeuroPace, Inc. NPCE released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic generalized epilepsy (IGE).The study met its primary 12-week post-implant safety endpoint, demonstrating a low rate of serious adverse events related to the device and implant procedure.The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to s ...